Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Avriel Linane

Neurology Pasadena, CA Doctor of Osteopathy

NPI 1912135104 CMS profile 1285820

625 S Fair Oaks Ave, #325, Pasadena, CA 91105

Open in the dashboard

General payments

$8,185

352 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Avriel Linane of Pasadena, CA is reported in the CMS Open Payments database as having received $8,185 across 352 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $71 3
2023 General $2,064 76
2022 General $2,315 94
2021 General $1,890 96
2020 General $462 21
2019 General $1,382 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Avriel Linane
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Avriel Linane were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Avriel Linane Neurology median Middle half National median
2019 $1,382 $474 $118–$2,177 $163
2020 $462 $367 $82–$2,309 $114
2021 $1,890 $438 $104–$2,547 $132
2022 $2,315 $442 $103–$2,388 $149
2023 $2,064 $464 $119–$2,312 $160
2024 $71 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. UCB, Inc. $1,413 61 payments
  2. AbbVie, Inc. $775 34 payments
  3. SK Life Science, Inc. $412 17 payments
  4. Novartis Pharmaceuticals Corporation $400 19 payments
  5. Sunovion Pharmaceuticals Inc. $337 17 payments
  6. Teva Pharmaceuticals USA, Inc. $316 16 payments
  7. Neurocrine Biosciences, Inc. $295 11 payments
  8. Eisai Inc. $294 14 payments
  9. Sumitomo Pharma America, Inc. $283 12 payments
  10. Allergan Inc. $240 9 payments
  11. Other $3,421 142 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $8,135 350 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50 2 payments
Products named General payments · program years 2019–2024
  1. Briviact $895 35 payments
  2. APTIOM $555 26 payments
  3. AIMOVIG $308 15 payments
  4. BOTOX $251 9 payments
  5. Fycompa $250 12 payments
  6. UBRELVY $243 12 payments
  7. Fintepla $241 7 payments
  8. Vimpat $221 17 payments
  9. QULIPTA $216 10 payments
  10. ZEPOSIA $200 9 payments
  11. Other $5,007 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

249

Median for Psychiatry & Neurology: 100

Drug cost

$43,582

Median for Psychiatry & Neurology: $2,986

Branded share of claims

15.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 11 $21,580
Ubrelvy Ubrogepant Brand 15 $14,443
Levetiracetam Generic 43 $2,003
Rivastigmine Rivastigmine Tartrate Brand 13 $1,919
Divalproex Sodium Generic 24 $1,344
Memantine Hcl Generic 44 $1,058
Gabapentin Generic 28 $369
Donepezil Hcl Generic 36 $358
Lamotrigine Generic 22 $347
Atorvastatin Calcium Generic 13 $159

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $24
$24 — —
ZAVZPRET
  • PFIZER INC. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

352 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record